文献速递自身炎症与 IgG4 相关病

导致APLAID综合征且对TNF抑制剂有反应的新型致病性PLCG2变异特征分析

Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF Inhibitor.
PubMed 文献 · Arthritis Rheumatol · 2024-08-06

本研究在一名APLAID综合征患者中鉴定出新型PLCG2 p.D993Y变异,通过单细胞RNA测序及多种功能实验证实该变异为功能获得性突变,可破坏PLCG2自抑制并激活多条炎症信号通路。原文摘要报告该患者对TNF抑制剂有反应。

要点

  • 在APLAID患者中鉴定出新型PLCG2 p.D993Y变异。
  • 该变异通过破坏自抑制导致PLCG2自激活。
  • 患者对TNF抑制剂有反应。

核心结论

  • PLCG2 D993Y变异通过损害自抑制导致功能获得性突变,激活多条炎症信号通路,从而导致APLAID综合征。

研究设计与样本

  • 对一名APLAID综合征患者采用全外显子测序和Sanger测序鉴定致病变异,并使用单细胞RNA测序、免疫印迹、荧光素酶试验、肌醇单磷酸酶联免疫吸附试验、钙流试验、定量PCR和免疫共沉淀明确炎症特征并评估变异对蛋白功能和免疫信号的影响。

主要发现

  • 在患者中鉴定出新型新发变异PLCG2 p.D993Y,患者表现为结肠炎、全鼻窦炎、皮疹、水肿、反复呼吸道感染、B细胞缺陷和低丙种球蛋白血症。
  • 单细胞转录组显示患者外周血单核细胞炎症反应加剧。
  • 在HEK293T、COS-7和PLCG2敲除THP-1细胞系中表达D993Y变异显示PLCγ2磷酸化增强、肌醇-1,4,5-三磷酸产生和细胞内Ca2+释放升高,以及MAPK、NF-κB和NFAT信号通路激活,均较对照转染细胞增强。
  • 体外实验表明D993Y变异改变氨基酸性质,破坏PLCγ2催化域与自抑制域之间的相互作用,导致PLCγ2自激活。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Autoinflammation and phospholipase C (PLC) γ2-associated antibody deficiency and immune dysregulation (APLAID) syndrome is an autoinflammatory disease caused by gain-of-function variants in PLCG2. This study investigates the pathogenic mechanism of a novel variant of PLCG2 in a patient with APLAID syndrome. METHODS: Whole-exome sequencing and Sanger sequencing were used to identify the pathogenic variant in the patient. Single-cell RNA sequencing, immunoblotting, luciferase assay, inositol monophosphate enzyme-linked immunosorbent assay, calcium flux assay, quantitative PCR, and immunoprecipitation were used to define inflammatory signatures and evaluate the effects of the PLCG2 variant on protein functionality and immune signaling. RESULTS: We identified a novel de novo variant, PLCG2 p.D993Y, in a patient with colitis, pansinusitis, skin rash, edema, recurrent respiratory infections, B-cell deficiencies, and hypogammaglobulinemia. The single-cell transcriptome revealed exacerbated inflammatory responses in the patient's peripheral blood mononuclear cells. Expression of the D993Y variant in HEK293T, COS-7, and PLCG2 knock-out THP-1 cell lines showed heightened PLCγ2 phosphorylation; elevated inositol-1,4,5-trisphosphate production and intracellular Ca2+ release; and activation of the MAPK, NF-κB, and NFAT signaling pathways compared with control-transfected cells. In vitro experiments indicated that the D993Y variant altered amino acid properties, disrupting the interaction between the catalytic and autoinhibitory domains of PLCγ2, resulting in PLCγ2 autoactivation. CONCLUSION: Our findings demonstrated that the PLCG2 D993Y variant is a gain-of-function mutation via impairing its autoinhibition, activating multiple inflammatory signaling pathways, thus leading to APLAID syndrome. This study further broadens the molecular underpinnings and phenotypic spectrum of PLCγ2-related disorders.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Yang Z, Tao P, Han X, et al. Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF Inhibitor. Arthritis Rheumatol. 2024. PMID: 38965708. doi:10.1002/art.42948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。